AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7913970 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole treatment for 3-13 months
Number of subjects: 0
Study 3061974 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.25-2 mg, administered intravenously or intramuscularly)
Number of subjects: 0
Study 3061974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucagon
Number of subjects: 0
Study 3061974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular glucagon
Number of subjects: 0
Study 3061974 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29949232 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin (2 capsules, 5 mg each) once a day for 12 weeks
Number of subjects: 54
Study 27912901 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Number of subjects: 1329
Study 27912901 — intervention group
Group type: COMPARATOR
Intervention: Follitropin alfa
Number of subjects: 1329
Study 25842795 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-return catheter valve
Number of subjects: 96
Study 25842795 — intervention group
Group type: COMPARATOR
Intervention: Standard urine bag
Number of subjects: 96
Study 24005956 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 50 mg QD with PegIFNα‐2a/RBV for 24 weeks
Number of subjects: 92
Study 24005956 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 100 mg QD with PegIFNα‐2a/RBV for 24 weeks
Number of subjects: 92
Study 24005956 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα‐2a/RBV for 48 weeks (PR48 group)
Number of subjects: 92
Study 21761708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of correction of deviated nasal septum and plasma radiofrequency ablation
Number of subjects: 116
Study 21761708 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy of deviated nasal septum and partial inferior turbinectomy
Number of subjects: 116
Study 19476470 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide/metformin FDC tablet BID
Number of subjects: 561
Study 19476470 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone/metformin FDC tablet BID
Number of subjects: 561
Study 17326356 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric iris-fixated phakic intraocular lens implantation
Number of subjects: 40
Study 15179410 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg subcutaneously, administered twice daily on days 1 to 7)
Number of subjects: 12
Study 11486699 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated-liposomal doxorubicin (PLD)
Number of subjects: 258
Study 11486699 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin, bleomycin, and vincristine (ABV)
Number of subjects: 258
Study 9931845 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal procedure
Number of subjects: 98
Study 9931845 — intervention group
Group type: COMPARATOR
Intervention: Conventional open repair
Number of subjects: 98
Study 7657854 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-mg orlistat three times a day for 4 1/3 days
Number of subjects: 12
Study 7657854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2713970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2713970 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 24
Study 2713970 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 24
Study 2713970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold environment (‐8 degrees C)
Number of subjects: 24
Study 797075 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Number of subjects: 99
Study 797075 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly continuation chemotherapy with streptomycin and isoniazid for 12 or 18 months
Number of subjects: 99
Study 797075 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 99
Study 31610995 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail alert sent to physician
Number of subjects: 3595
Study 31610995 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (control group)
Number of subjects: 3595
Study 31386686 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic individuals
Number of subjects: 0
Study 31386686 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic individuals
Number of subjects: 0
Study 31386686 — intervention group
Group type: COMPARATOR
Intervention: Children aged 0-5
Number of subjects: 0
Study 28745783 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine intravenous catheter fixation
Number of subjects: 110
Study 28745783 — intervention group
Group type: COMPARATOR
Intervention: Modified intravenous catheter fixation
Number of subjects: 110
Study 26291952 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated active electrode/camera cords
Number of subjects: 84
Study 26291952 — intervention group
Group type: COMPARATOR
Intervention: Parallel oriented active electrode/camera cords
Number of subjects: 84
Study 23958390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus metformin
Number of subjects: 3312
Study 23958390 — intervention group
Group type: COMPARATOR
Intervention: Up-titration of metformin monotherapy
Number of subjects: 3312
Study 21111399 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine-timolol
Number of subjects: 1159
Study 21111399 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 1159
Study 21111399 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 1159
Study 19172219 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (45 mg daily for 6 months)
Number of subjects: 109
Study 19172219 — intervention group
Group type: COMPARATOR
Intervention: Calcium aspartate (133.8 mg of elemental calcium daily)
Number of subjects: 109
Study 17234537 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of lycopene (Group A, n = 21)
Number of subjects: 58
Study 17234537 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of lycopene along with biweekly intralesional steroid injections (Group B, n = 19)
Number of subjects: 58
Study 17234537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C, n = 18)
Number of subjects: 58
Study 11562416 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 354
Study 11562416 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + steroids (dual therapy)
Number of subjects: 354
Study 11562416 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA + steroids + azathioprine (triple therapy)
Number of subjects: 354
Study 11562416 — intervention group
Group type: COMPARATOR
Intervention: CsA monotherapy with steroids added
Number of subjects: 354
Study 9565278 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentine bonding agent (DBA)
Number of subjects: 16
Study 9565278 — intervention group
Group type: COMPARATOR
Intervention: Control tooth treated with DBA applied to coronal enamel
Number of subjects: 16
Study 9202801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Fat Emulsion 4501
Number of subjects: 20
Study 9202801 — intervention group
Group type: COMPARATOR
Intervention: Intralipid
Number of subjects: 20
Study 9202801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost dose in breast conserving therapy
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment planning techniques
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of wedge filters
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Collimator rotation and/or table wedge
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose specification
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung density corrections
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning system issues
Number of subjects: 16
Study 1792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose recalculation
Number of subjects: 16
Study 7194655 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 422
Study 7194655 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 422
Study 31934996 — intervention group
Group type: EXPERIMENTAL
Intervention: siponimod
Number of subjects: 94
Study 31934996 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 94
Study 27988390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical therapy with adjunctive metronidazole
Number of subjects: 161
Study 27988390 — intervention group
Group type: COMPARATOR
Intervention: Mechanical therapy without adjunctive metronidazole
Number of subjects: 161
Study 26013203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation (AA)
Number of subjects: 101
Study 26013203 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant switching (SW)
Number of subjects: 101
Study 26013203 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole augmentation (AA) and Antidepressant switching (SW)
Number of subjects: 101
Study 24725616 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro low mixture (LM25) twice daily
Number of subjects: 476
Study 24725616 — intervention group
Group type: COMPARATOR
Intervention: Basal-prandial regimen of insulin glargine once daily and insulin lispro once daily (IGL)
Number of subjects: 476
Study 24725616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 476
Study 22032650 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoactivated tissue bonding (PTB)
Number of subjects: 31
Study 22032650 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 31
Study 20927140 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive posterior approach
Number of subjects: 50
Study 20927140 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterior approach
Number of subjects: 50
Study 18360287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent HAART (arm B)
Number of subjects: 37
Study 18360287 — intervention group
Group type: COMPARATOR
Intervention: Continuous HAART (arm A)
Number of subjects: 37
Study 15761427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at minimum purpura dose (MPD)
Number of subjects: 17
Study 15761427 — intervention group
Group type: EXPERIMENTAL
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 17
Study 15761427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser at fluences greater than MPD
Number of subjects: 17
Study 12211668 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients with no preoperative contamination
Number of subjects: 41
Study 10334141 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation feedback during rebreathing 7% CO2/93% O2
Number of subjects: 30
Study 10334141 — intervention group
Group type: COMPARATOR
Intervention: No feedback session
Number of subjects: 30
Study 8922875 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated 2-rod Norplant implant
Number of subjects: 0
Study 8922875 — intervention group
Group type: EXPERIMENTAL
Intervention: Original 2-rod Norplant implant
Number of subjects: 0
Study 8922875 — intervention group
Group type: COMPARATOR
Intervention: Both implants
Number of subjects: 0
Study 1417482 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranormal values of cardiac index (> or = 4.52 L/min per square meter), oxygen delivery (> or = 670 mL/min per square meter), and oxygen consumption (> or = 166 mL/min per square meter)
Number of subjects: 67
Study 1417482 — intervention group
Group type: COMPARATOR
Intervention: Normal values for all hemodynamic measurements (control group)
Number of subjects: 67
Study 1417482 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranormal values
Number of subjects: 67
Study 4084899 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (mean daily dose 3.78 mg)
Number of subjects: 54
Study 4084899 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (mean daily dose 208 mg)
Number of subjects: 54
Study 4084899 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 54
Study 4084899 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 54
Study 4084899 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam and Desipramine
Number of subjects: 54
Study 28906348 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 11
Study 28906348 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 28954546 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer facilitators
Number of subjects: 225
Study 28954546 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert facilitators
Number of subjects: 225
Study 26505413 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly selected gene groups (1000, 100, 50, 30, 10, 5, and 3 genes selected 1000 times)
Number of subjects: 53
Study 24239841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation management (AM) with phased RF ablation
Number of subjects: 210
Study 24239841 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 210
Study 24239841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation management (AM)
Number of subjects: 210
Study 24239841 — intervention group
Group type: COMPARATOR
Intervention: Ablation management (AM) and Medical management (MM)
Number of subjects: 210
Study 22612526 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 631
Study 20014607 — intervention group
Group type: EXPERIMENTAL
Intervention: ProAct (PA) laryngeal mask airway
Number of subjects: 120
Study 20014607 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditech Systems Limited (MSL) laryngeal mask airway
Number of subjects: 120
Study 20014607 — intervention group
Group type: COMPARATOR
Intervention: Classic Laryngeal Mask Airway (cLMA)
Number of subjects: 120
Study 17484740 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention guided by the Levine Conservation Model; details on dosage and duration not specified.
Number of subjects: 0
Study 15192321 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) infusion
Number of subjects: 12
Study 15192321 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 11336588 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) co-administered with nucleoside reverse transcriptase inhibitors (nRTIs)
Number of subjects: 0
Study 11336588 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) co-administered with ritonavir
Number of subjects: 0
Study 11336588 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) co-administered with nelfinavir
Number of subjects: 0
Study 11336588 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase) with ritonavir
Number of subjects: 0
Study 11336588 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (Fortovase)
Number of subjects: 0
Study 11336588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir and saquinavir
Number of subjects: 0
Study 8365284 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aerosolized pentamidine once monthly
Number of subjects: 151
Study 8365284 — intervention group
Group type: COMPARATOR
Intervention: 300 mg aerosolized pentamidine twice monthly
Number of subjects: 151
Study 8365284 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prophylaxis (one prior episode of PCP)
Number of subjects: 151
Study 8365284 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (300 mg) prophylaxis
Number of subjects: 151
Study 8365284 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine
Number of subjects: 151
Study 3534025 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin)
Number of subjects: 0
Study 3534025 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of topical sunscreen preparations
Number of subjects: 0
Study 3534025 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension of oral contraceptives and other agents that promote skin pigmentation
Number of subjects: 0
Study 3534025 — intervention group
Group type: COMPARATOR
Intervention: Monobenzyl ether of hydroquinone
Number of subjects: 0
Study 30047176 — intervention group
Group type: EXPERIMENTAL
Intervention: Small‐sided ball games (SSG)
Number of subjects: 291
Study 30047176 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit strength training (CST)
Number of subjects: 291
Study 30047176 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 291
Study 27488098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh oranges (1774 μmol of total Citrus flavanones)
Number of subjects: 12
Study 27488098 — intervention group
Group type: COMPARATOR
Intervention: Pasteurized orange juice (751 μmol of total Citrus flavanones)
Number of subjects: 12
Study 27488098 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (fresh oranges and orange juice)
Number of subjects: 12
Study 27488098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh oranges
Number of subjects: 12
Study 25322597 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) based comprehensive treatment
Number of subjects: 50
Study 25322597 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study 23106412 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) twice a week
Number of subjects: 141
Study 23106412 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) once a week
Number of subjects: 141
Study 23106412 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 141
Study 21968659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% THPE-containing cream
Number of subjects: 41
Study 21968659 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 41
Study 18334820 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 0
Study 18334820 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study 16566965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lignocaine gel with 0.05% chlorhexidine gluconate (group 1, n = 72)
Number of subjects: 141
Study 16566965 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 2% lignocaine and aqueous gel mixture (group 2, n = 69)
Number of subjects: 141
Study 14738340 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hand tracking on Test 1
Number of subjects: 76
Study 14738340 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hand tracking on Test 2
Number of subjects: 76
Study 14738340 — intervention group
Group type: COMPARATOR
Intervention: Left hand tracking on Test 1
Number of subjects: 76
Study 14738340 — intervention group
Group type: COMPARATOR
Intervention: Right hand tracking on Test 2
Number of subjects: 76
Study 10623705 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine, three weekly intradermal vaccine injections of 10^7 irradiated autologous tumor cells and 10^7 BCG organisms for the first two injections
Number of subjects: 412
Study 10623705 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine
Number of subjects: 412
Study 10623705 — intervention group
Group type: COMPARATOR
Intervention: Observation arm (control)
Number of subjects: 412
Study 9186094 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital image analysis for measuring corneal haze
Number of subjects: 20
Study 1326404 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg sumatriptan sc
Number of subjects: 27
Study 1326404 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 3493795 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at varying rates (60 to 200 micrograms kg‐1 min‐1)
Number of subjects: 72
Study 3493795 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 72
Study 29498457 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (n=64)
Number of subjects: 128
Study 29498457 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=61)
Number of subjects: 128
Study 27593863 — intervention group
Group type: EXPERIMENTAL
Intervention: New nomogram including albumin, base excess, and respiratory rate
Number of subjects: 561
Study 27593863 — intervention group
Group type: EXPERIMENTAL
Intervention: New nomogram
Number of subjects: 561
Study 27593863 — intervention group
Group type: COMPARATOR
Intervention: Conventional scoring system
Number of subjects: 561
Study 26159999 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of cLQTS-associated variants
Number of subjects: 870
Study 26159999 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of cLQTS-associated variants
Number of subjects: 870
Study 23988639 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan treatment among patients with low eGFR
Number of subjects: 18666
Study 23988639 — intervention group
Group type: COMPARATOR
Intervention: Low eGFR
Number of subjects: 18666
Study 21297492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 134
Study 21297492 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 134
Study 21297492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe plus Simvastatin
Number of subjects: 134
Study 21297492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 19076931 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IgE treatment
Number of subjects: 25
Study 19076931 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25